INIS
patients
100%
anticoagulants
86%
plasma
47%
thrombin
44%
risks
33%
blood cells
33%
drugs
31%
thrombosis
28%
applications
27%
phospholipids
25%
reviews
18%
production
17%
heparin
16%
concentration
16%
assessments
16%
tissues
15%
performance
15%
venoms
15%
complement
14%
comparative evaluations
13%
storage
13%
evaluation
13%
electrodes
13%
stability
13%
screening
13%
particles
13%
information
12%
leukemia
11%
laboratories
11%
vitamin k
10%
doses
10%
hemolysis
8%
death
8%
diseases
8%
control
8%
values
7%
transfusions
7%
freezing
6%
origin
6%
implementation
6%
sensitivity
6%
testing
6%
monitoring
5%
kidneys
5%
interactions
5%
variations
5%
blood
5%
proteins
5%
monoclonal antibodies
5%
range
5%
Keyphrases
Non-valvular Atrial Fibrillation
13%
Prescribing Appropriateness
13%
Rapid Estimation
13%
ST Genesia
13%
Analytical Samples
13%
Performance Stability
13%
Dilute Russell's Viper Venom Time
13%
Thrombophilia Screening
13%
Paroxysmal Nocturnal Hemoglobinuria
13%
Longitudinal Clinical Study
13%
Prospective Longitudinal Study
13%
Platelet-derived Microparticles
13%
Non-vitamin K Antagonist Oral Anticoagulants
13%
Preventive Strategies
13%
Preventability
13%
Promyelocytic
13%
Hypercoagulable State
13%
Red Cell Concentrates
13%
Direct Oral Anticoagulants
13%
Clinical Pharmacist
10%
Serotonin Release Assay
9%
Platelet-free Plasma
7%
Serious Adverse Drug Reaction
7%
Potentially Preventable
7%
Routine Monitoring
6%
Drug Approval
6%
Decreased Risk
6%
Author Information
6%
Last Name
6%
First Names
6%
Unfractionated Heparin
6%
Vesicle Production
5%
Preventable Adverse Events
5%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
40%
Paroxysmal Nocturnal Hemoglobinuria
27%
Eculizumab
27%
Thromboembolism
25%
Procoagulant
25%
Direct Oral Anticoagulant
23%
Bleeding
14%
Prospective Study
13%
Adverse Drug Reaction
13%
Drug Concentration
13%
Heparin
13%
Heparin Induced Thrombocytopenia
13%
Viper Venom
13%
Antivitamin K
10%
Thrombin
10%
Phospholipid
10%
Toxic Injury
9%
Drug Interaction
8%
Drug Approval
6%
Rivaroxaban
6%
Prevalence
6%
Dabigatran
6%
Apixaban
6%